Mesna Eg

Mesna, the active ingredient in Mesna Eg, is a thiol‑containing chemoprotective agent presented as an intravenous solution for intravenous use. It is employed to protect the bladder from toxic metabolites generated during certain chemotherapy regimens. GNH USA supplies Mesna Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mesna is used to protect the urinary tract during chemotherapy that produces acrolein, a urotoxic metabolite. - Hemorrhagic cystitis caused by cyclophosphamide: prevents bladder toxicity and bleeding. - Hemorrhagic cystitis caused by ifosfamide: reduces risk of bladder irritation and hemorrhage. - Acrolein‑mediated bladder toxicity: provides uroprotection during high‑dose alkylating agent therapy.

Mesna is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea or vomiting. - Mild headache. - Transient hypotension. - Metallic taste in the mouth. - Mild skin rash.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Hemolysis in patients with G6PD deficiency. - Severe hypotension or shock. - Pulmonary edema. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute renal failure.

Mesna should be used with attention to the following safety considerations. - Renal function: monitor urine output and renal parameters during therapy. - G6PD deficiency: avoid use because of risk of hemolysis. - Concurrent chemotherapy: coordinate timing with cyclophosphamide or ifosfamide administration. - Allergy: discontinue immediately if signs of hypersensitivity appear. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus (category unknown). - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mesna may interact with other agents that affect oxidative balance or renal clearance.

Major Interactions (Avoid): - Co‑administration with high‑dose methylene blue: may reduce Mesna’s protective effect. - Use with nephrotoxic drugs in patients with severe renal impairment: may increase Mesna accumulation.

Moderate Interactions (Monitor Closely): - Concurrent thiol‑containing agents (e.g., N‑acetylcysteine): may increase risk of adverse reactions. - High‑dose vitamin C supplementation: could interfere with acrolein binding. - Loop diuretics: may alter urinary excretion of Mesna and require dose adjustment.